Akebia Therapeutics Inc.

NASDAQ:AKBA   3:59:55 PM EDT
3.05
+0.09 (+3.04%)
Products

Akebia Submits New Drug Application (NDA) To The FDA For Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease In Adult Patients On Dialysis And Not On Dialysis

Published: 03/30/2021 11:20 GMT
Akebia Therapeutics Inc. (AKBA) - Akebia Submits New Drug Application (nda) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis.
Akebia Therapeutics Inc - Company's NDA Submission Did Not Include a Priority Review Voucher.
Akebia Therapeutics Inc - Company's NDA Submission Did Not Include a Priority Review Voucher.
Akebia Therapeutics - Otsuka Pharmaceutical Working in Close Collaboration With Co to Prepare a Maa for Vadadustat for Submission to Ema.